المؤلفون: Burmester GR; Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin, Berlin, Germany., Strand V; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA., Kivitz AJ; Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, USA., Hu CC; Sanofi, Bridgewater, NJ, USA., Wang S; Sanofi, Bridgewater, NJ, USA., van Hoogstraten H; Sanofi, Bridgewater, NJ, USA., Klier GL; Sanofi, Bridgewater, NJ, USA., Fleischmann R; University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, USA.

المصدر: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2023 Oct 03; Vol. 62 (10), pp. 3268-3279.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 100883501 Publication Model: Print Cited Medium: Internet ISSN: 1462-0332 (Electronic) Linking ISSN: 14620324 NLM ISO Abbreviation: Rheumatology (Oxford) Subsets: MEDLINE

مواضيع طبية MeSH: Arthritis, Rheumatoid*/drug therapy , Arthritis, Rheumatoid*/chemically induced , Antirheumatic Agents*/adverse effects , Neutropenia*/epidemiology, Humans ; Antibodies, Monoclonal, Humanized/adverse effects ; Treatment Outcome ; Methotrexate/therapeutic use